Initial results will be available in about six weeks.
Medigus Ltd. (TASE:MDGS announced the completion of initial human trials for its product to treat Gastroesophageal Reflux Disease (GERD). The company ran trials on four patients and is expecting the results within six weeks. The trials were conducted by Professor David Watson of the Flinders Medical Centre, Adelaide Australia. The results of the trials will determine whether the company will continue with additional trials in Europe and the US in order to apply for US Food and Drug Administration approval for the treatment and for marketing of the device.
Medigus developed an endoscopic device to replace the need for surgery for stapling the stomach, which is the current treatment for cases of extreme GERD. The device already has CE Mark safety certification and can be marketed in Europe; however the company is waiting for FDA approval before it begins to market the device.
Published by Globes [online], Israel business news - www.globes.co.il - on August 22, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006